UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...

UK pharma major AstraZeneca and Japanese drugmaker Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has won conditional approval in China as a monotherapy for the treatment of adult patients with ...

A study in *The New England Journal of Medicine* reported seven blood cancer cases in patients treated with bluebird bio's ...

French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive ...

Roche presented positive two-year data from the RAINBOWFISH study on Evrysdi (risdiplam) for spinal muscular atrophy (SMA) in ...

Indian drugmaker Wockhardt’s today announced that the Subject Expert Committee (SEC) of Indian drug regulator, Central Drugs ...

Stealth BioTherapeutics received a favorable vote from an FDA advisory committee for elamipretide, aimed at treating Barth ...

Boston-based Upstream Bio debuted on Nasdaq with shares opening 26.5% above its IPO price, valuing the firm at $1.05 billion.

The Danish Medicines Council forecasts processing times for treatment evaluations will rise from 19 to 27 weeks by Q1 2025 ...

Turnstone Biologics (Nasdaq: TSBX) is restructuring operations, cutting 60% of its workforce to focus on its lead program, ...

The FDA has approved new 2mL pre-filled syringes and autoinjectors for UCB's Bimzelx (bimekizumab-bkzx) to treat psoriasis. Each contains 320mg, offering single-injection options alongside existing ...

Shares of French biotech Transgene (tumbled 13.5% to 1.01 euros by late morning after it announced that its randomized Phase ...